UK biotech finishes on high despite challenging 2025

UK biotech has demonstrated resilience in a challenging 2025 and enters 2026 with renewed confidence and broadening investor appetite, the BioIndustry Association’s (BIA) report UK biotech financing 2025 has found.

The UK biotech sector has emerged from one of its most selective investment climates in a decade, ending 2025 with clear signs of renewed momentum and increased investor confidence. The UK firmly retained it//s position as Europe’s leading national biotech market throughout the year, representing 30% of all European venture financing, despite a 13.2% year‑on‑year drop in venture capital investment, totalling £1.79 billion ($2.41 billion) across 58 deals.

While much of 2025 was characterized by investor caution, the final quarter delivered an unmistakable shift. The fourth quarter recorded 22 completed deals – the highest quarterly deal count of the year – indicating positive investor sentiment going into 2026. This renewed deal flow signals the beginning of a healthier distribution of capital across the biotech ecosystem.